Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
JAMA|March 27, 2007
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam, Mihai Gheorghiade, John C Burnett, et al.JAMA|March 27, 2007
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status TrialsMihai Gheorghiade, Marvin A Konstam, John C Burnett, et al.Heart Failure Reviews|September 21, 2011
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trialMihai Gheorghiade, Peter S Pang, Andrew P Ambrosy, et al.American Journal of Therapeutics|July 17, 2010
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fractionNorman C Wang, Jonathan P Piccini, Marvin A Konstam, et al.Journal of the American College of Cardiology|November 11, 2008
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) programJohn E A Blair, Faiez Zannad, Marvin A Konstam, et al.JAMA|June 12, 2008
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fractionNorman C Wang, Aldo P Maggioni, Marvin A Konstam, et al.European Heart Journal|January 8, 2013
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trialAndrew P Ambrosy, Peter S Pang, Sadiya Khan, et al.European Heart Journal|July 26, 2011
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trialJohn E A Blair, Peter S Pang, Robert W Schrier, et al.International Journal of Biological Macromolecules|June 23, 2023
Boosting the photodynamic activity of erythrosine B by using thermoresponsive and adhesive systems containing cellulose derivatives for topical deliveryJéssica Bassi da Silva, Rafaela Said Dos Santos, Camila Felix Vecchi, et al.American Heart Journal|May 4, 2010
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) programChristopher M O'Connor, Alan B Miller, John E A Blair, et al.Pageof 7